Systemic chemotherapy plays a central role in the management of metastatic bladder cancer. Although responses may be observed initially, overall survival with multiagent chemotherapy is still limited. No significant improvements have been made by novel cytotoxic or targeted agents in last decade. There exists an urgent need for the development of novel therapeutic agents to improve outcomes for these patients. In this paper, we review the role of immunotherapy, the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2), and ongoing drug development efforts to block this pathway in bladder cancer, focusing on the currently available data from ongoing clinical trials.
Introduction
Bladder cancer is the most common malignant disease involving the urinary system. Approximately 74,690 patients will be diagnosed with bladder cancer in 2014 ("SEER Stat Fact Sheets: Bladder Cancer", 2014) . About one third of bladder cancer patients develop locally invasive or metastatic disease (Raghavan, 2003) . Systemic chemotherapy is the standard approach for patients with inoperable locally advanced or metastatic bladder cancer. Although responses may be observed initially, the median survival with multiagent chemotherapy is about 13 months (Loehrer et al., 1992) . In Europe, vinflunine is approved as a treatment option for patients with advanced urothelial cancer who have failed a prior platinum-containing regimen (Bellmunt et al., 2009 ). To date, in the USA, there is no Food and Drug Administration (FDA) approved second-line chemotherapy for patients with metastatic bladder cancer and guidelines continue to emphasize patient enrollment into a clinical trial. Active single agents not incorporated in the initial regimen may have activity in some patients.
There had been a plateau in the development of new effective agents for this aggressive malignancy. While there is an increasing understanding of the molecular biology and signaling pathways underlying bladder cancer development and progression, no targeted agents currently have proven a significant role in the treatment of urothelial bladder cancer. There is increasing evidence that some tumors can evade adaptive immunity and disrupt T-cell checkpoint pathways. More recently, efforts have targeted and activated the immune system to treat various malignancies. It is imperative to develop more effective, less toxic agents by incorporating these novel findings to improve outcomes in bladder cancer.
In this paper, we review the role of immunotherapy, the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2), and ongoing drug development efforts to block this pathway in bladder cancer, focusing on the currently available data from ongoing clinical trials. local immune response as evidenced by infiltration of bladder with inflammatory cells (Mitropoulos, 2005) . A significant urinary secretion of several cytokines can be detected within 24 hours of BCG instillation, with a maximum titer after 2-8 hours and a decrease to normal values within 24 hours (Taniguchi et al., 1999) . This sharp rise in urine level of cytokines after BCG instillation is suggestive of the immunological character of a BCG therapy (Elsasser-Beile et al., 2000) . The presence of CD4+ helper, CD8+ cytolytic T cells and natural killer cells is necessary to induce antitumor effects (Ratliff, Gillen, & Catalona, 1987) . Once an effective TH1 cellular response has been generated, cellular activation leads to amplification of effector cells that are capable of eliminating bladder cancer cells and producing cytokines to regulate immune response.
The American Urological Association and the European Association of Urology bladder cancer guidelines recommend a course of intravesical BCG for patients with stage T1, Tis and high-grade Ta tumors (Babjuk et al., 2008; Hall et al., 2007) . The short-term and long-term efficacy of BCG in the treatment of patients with superficial bladder cancer has been extensively studied. It has been shown to delay tumor progression (and a need for subsequent cystectomy) and improve overall survival (Herr, 1997) . The survival rate at five years following BCG treatment is similar to that achieved after immediate cystectomy in these patients. In a systematic review of 585 patients with Ta or T1 disease that were involved in six randomized trials, BCG had significantly fewer recurrences at 12 months (Shelley et al., 2000) . Intravesical BCG also significantly reduces the risk of long-term treatment failure. This was demonstrated in a meta-analysis of 700 patients with carcinoma in situ who were treated in nine randomized trials, 68% patients achieved a complete response with the BCG (Sylvester, van der Meijden, Witjes, & Kurth, 2005) . After a median followup of 3.6 years, 46.7% patients with prior BCG had no evidence of disease.
Unfortunately, nearly 40% of patients with superficial bladder cancer will fail BCG therapy (Witjes, 2006) . There are many reasons cited for BCG failure including insufficient treatment, occult invasive or metastatic disease, inadequate immune response, gradual waning of the immune response or natural resistance associated macrophage protein 1 (NRAMP1) gene polymorphism (Zlotta, Fleshner, & Jewett, 2009) . By acknowledging the limitations of BCG and with the newer discoveries in human cancer immunology, significant efforts are currently being made to again transform the treatment of advanced bladder cancer.
Targetting Cytotoxic T-lymphocyte Antigen 4 (CTLA-4)
The BCG success story paves the way to further explore a potential role of immunotherapeutic agents for advanced bladder cancer. In the last decade, much has been learned about the immunobiology of various tumors. Most of the discoveries in human cancer immunology originate from studies of melanoma, a cancer shown to be among the most immunogenic of all tumors. The potential therapeutic role of immunotherapy in augmenting the antitumor immune responses against cancer continues to expand. We have learned that the activation of cellular immunity begins when T cells recognize peptide fragments of intracellular proteins that are expressed on the surface of antigen presenting cells bound to specific major histocompatibility complex molecules (L. Chen & Flies, 2013) . This interaction requires the presence of a costimulatory molecule (B7) and activation results in upregulation of CTLA-4. The CTLA-4 receptor on T lymphocytes is a negative regulator of T cell activation that outcompetes CD28 for binding to B7 on antigen presenting cells (Peggs, Quezada, Korman, & Allison, 2006) . CTLA-4 thereby serves as a physiologic "control" on the activated immune system.
Ipilimumab is a monoclonal antibody to CTLA-4 that can prevent this feedback inhibition, resulting in an immune response against the tumor. Treatment with ipilimumab significantly increases median overall survival in both previously untreated and treated patients with metastatic melanoma (Hodi et al., 2010) . Immune monitoring studies of patients with bladder cancer who were treated with two cycles of preoperative ipilimumab, have shown that treatment with anti-CTLA-4 antibody leads to an increase in the population of CD4+ inducible costimulator cells (CD4+ICOShi) in both tumor tissues and peripheral blood (Carthon et al., 2010) . The preliminary data also indicated that an increased frequency of CD4+ inducible costimulator cells correlated with increased likelihood of clinical benefit. Further work is needed to investigate its role as a potential biomarker for correlation with clinical outcome in patients with metastatic disease who receive treatment with anti-CTLA-4. Ipilimumab related adverse events observed in this study were mostly reversible and manageable. Ipilimumab is currently being evaluated in a Phase II study in combination with cisplatin and gemcitabine for advanced urothelial cancer ("Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU10-148").
PD-1 Pathway Inhibitors
Encouraging clinical data have demonstrated that therapies focused on enhancing T-cell responses against cancer can result in a significant survival benefit in patients with advanced cancer (Chen, Irving, & Hodi, 2012; Hodi et www.ccsenet.org/cco Cancer and Clinical Oncology Vol. 3, No. 2; 2014 al., 2010). PD-1 is an inhibitory receptor expressed on T cells following T-cell activation, that is sustained in states of chronic stimulation such as in cancer (Blank & Mackensen, 2007) . PD-L1 is an extracellular protein that down regulates immune responses primarily in peripheral tissues through binding to its two receptors PD-1 and B7.1. Ligation of PD-L1 with PD-1 inhibits T-cell proliferation, cytokine production, and cytolytic activity, leading to the functional inactivation or exhaustion of T cells. B7.1 is a molecule expressed on antigen-presenting cells and activated T cells. PD-L1 binding to B7.1 on T cells and antigen-presenting cells can mediate downregulation of immune responses, including inhibition of T-cell activation and cytokine production (Butte, Keir, Phamduy, Sharpe, & Freeman, 2007; Yang et al., 2011) . PD-L1 expression is prevalent in many human tumors. Overexpression of PD-L1 on tumor cells has been reported to impede antitumor immunity, resulting in immune evasion (Blank & Mackensen, 2007) . Elevated PD-L1 expression on tumor cells is possibly associated with a poor prognosis in patients with bladder cancer (Mu, Huang, Chen, Chen, & Zhang, 2011) . Preclinical data has shown that interruption of the interaction between PD-L1 and PD-1 in mouse tumor models lead to antitumor effects (Iwai et al., 2002 ) (Strome et al., 2003) . Therefore, interruption of the PD-L1/PD-1 pathway represents an attractive strategy to reinvigorate tumor-specific T-cell immunity. Table 1 lists ongoing clinical trials of anti-PD-1 drugs for urothelial and other solid tumors. 
MPDL3280A
MPDL3280A (Roche) is an engineered anti-PD-L1 antibody. In the initial Phase I dose-escalation study involving 171 patients with locally advanced or metastatic tumors, no dose-limiting toxicities were observed and the maximum tolerated dose was not identified (Herbst et al., 2013) . Overall it was observed that patients with PD-L1 positive tumors (from archival samples) had a higher response rate as compared to PD-L1 negative tumors. It demonstrated a promising overall response rate in patients with metastatic bladder cancer whose tumors were characterized as PD-L1 positive (Powles et al., 2014) . The overall response rate was 52% in patients with previously treated metastatic PD-L1 positive bladder cancer as compared to 11% in patients who were PD-L1 negative. The median time to response was 42 days and complete response was observed in 7% of PD-L1 positive patients. In view of these spectacular results, the FDA granted MPDL3280A a breakthrough therapy designation in bladder cancer. Of note, it is for the first time that an agent has received this designation in bladder cancer.
Currently, studies with MPDL3280A are being designed to test for PD-L1 expression on tumor cells by immunohistochemistry (IHC) and analyze efficacy according to different IHC strata (ClinicalTrials.gov identifier: NCT01846416). A Phase II study of MPDL3280A is currently evaluating its role in patients with metastatic urothelial bladder cancer ("A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,"). This study will generate additional data in patients who are ineligible for platinum-containing therapy (treatment-naive) and those who have progressed following a prior platinum-based chemotherapy.
MEDI4736
MEDI4736 (AstraZeneca) is a human monoclonal antibody directed against PD-L1. An encouraging clinical activity was seen in a Phase I clinical trial of 26 patients with advanced solid tumors (Lutzky et al., 2014) . With a manageable toxicity profile, four confirmed partial responses and a disease control rate of 46% was observed. Again no DLTs or maximum tolerated dose were identified. Further development of this agent is underway with expansion cohorts for bladder cancer and multiple other tumor types. The preliminary safety and durable clinical efficacy profile of MEDI4736 has also led to initiation of a Phase III study in non-small cell lung cancer 
Nivolumab
Nivolumab (Bristol-Myers Squibb) is another agent of great interest and a fully human IgG4 monoclonal antibody against PD-1. A Phase I/II trial of nivolumab in combination with ipilimumab is currently enroling patients with bladder cancer ("A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors,"). Future role of this agent in bladder cancer will largely depend on the results of this study. The first-in-human Phase I study previously evaluated its safety and tolerability in 39 patients with advanced refractory solid tumors (Brahmer et al., 2010) . This agent was well tolerated to the maximum planned dose of 10 mg/kg; one durable complete response and two partial responses were observed. Subsequently, a large Phase I study in 207 patients also confirmed objective responses in patients with melanoma, non-small cell lung, and renal cancers (Brahmer et al., 2012) . Prolonged stabilization of disease at 24 weeks was observed in upto 41% patients. Nivolumab is currently in advanced stages of development in patients with malignant melanoma and renal cancer ("Study of Nivolumab vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma,").
Lambrolizumab
Lambrolizumab (Merck), also formerly known as MK-3475, is a humanized monoclonal IgG4 antibody that acts against PD-1. Its role in advanced bladder cancer is currently being evaluated ("Study of MK-3475 in Participants With Advanced Solid Tumors", 2014). Previously it received a breakthrough therapy designation from the FDA after promising results were seen in patients with advanced melanoma. MK-3475 is currently being studied in advanced triple negative breast, head and neck, and urothelial cancers ("Study of MK-3475 in Participants With Advanced Solid Tumors", 2014).
Conclusions
Because treatment with immunotherapy agents has lead to clinical responses in various cancers, it seems that immuno-oncology will dominate the oncology enterprise for the rest of this decade. Above discussed results www.ccsenet.org/cco Cancer and Clinical Oncology Vol. 3, No. 2; 2014 support further development of these agents for the treatment of patients with advanced bladder cancer. However, a predictive biomarker that can be used to select patients for treatment with these agents has not yet been identified. Expression of PD-L1 on immune cells or tumor cells may be potentially helpful, because a subset of patients who were deemed to be PD-L1 positive were found to have clinical responses with MPDL3280A (Powles et al., 2014) . The relationship between PD-L1 status and efficacy in patients with urothelial cancer warrants further exploration. Future high quality biomarker-driven clinical trials are essential for spearheading this new approach.
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